Transcription of Reference ID: 3101735
{{id}} {{{paragraph}}}
Example: marketing
Reference ID: 3101735
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use docetaxel Injection safely and effectively. See full prescribing information for docetaxel Injection. docetaxel Injection, Solution for Intravenous Infusion Initial Approval: 1996 WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel at 100 mg/m2 ( ) Should not be given if bilirubin > ULN, or if AST and/or ALT > x ULN concomitant with alkaline phosphatase > x ULN.
Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer . Docetaxel Injection as a single agent is indicated …
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: